Paris-based Sebia will distribute the Seralite-FLC (sFLC) cancer test that is used in the diagnosis and monitoring of the blood cancer myeloma. The annual global market for myeloma cancer test is £200m.
The sFLC test was developed in a joint venture with Birmingham based Abingdon Health and scientists at the University of Birmingham.
Sebia, which develops cancer tests and systems to detect metabolic disorders such as diabetes, will market sFLC in over 120 countries.
Chris Yates, CEO of Abingdon Health, which is based at the Birmingham Research Park in Edgbaston, said: “Existing tests have a turn around for results of up two weeks. With the sFLC test a clinician can have the result in around 10 minutes which reduces patient delays with the resulting delay in patient anxiety.
“The sFLC is competitive with existing systems in terms of price and speed which I believe gives us a competitive edge. We are delighted to join with Sebia as a global partner in the distribution of sFLC.
“Sebia’s global reach and market leadership in the provision of electrophoresis testing makes it the perfect partner to launch our new product worldwide.”
The sFLC test is prescribed to help detect, diagnose and monitor plasma cell disorders such as multiple myeloma, and to monitor the effectiveness of treatments. The financial terms of the agreement have not been disclosed.
Dr James Wilkie, CEO of Alta Innovations, the tech transfer arm of the University of Birmingham, said: “We have worked closely with Abingdon Health to bring these research results to market as fast as possible where they make a real difference to patients’ lives.
“This new agreement with Sebia makes this happen even more quickly.”]
Click below to receive daily regional business updates